Results 101 to 110 of about 170,256 (261)

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

Head &Neck, EarlyView.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell, E. C. Ward, L. R. Wishart, R. Perera, C. Barrett, K. A. Edmiston, E. Mitchell, A. Pigott, R. Pitt, K. Russell, B. A. Chan, R. Ladwa   +11 more
wiley   +1 more source

Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.

, 2020
BACKGROUND: As the number of indicated malignancies for which immune checkpoint inhibitor therapy such as pembrolizumab grows the descriptions of associated immune-related adverse events (irAEs) increases as well. On rare occasions immunotherapy can lead
Giri, Anshu, Puchalla, Jon, Kalmuk, James, Kaczmar, John, Feng, Gong, MD, PhD   +4 more
core   +1 more source

Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19‐09, CONPELAN Study

Head &Neck, EarlyView.
ABSTRACT Background The benefit of consolidation programmed cell death protein 1 (PD‐1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Methods Patients with stages II–IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy ...
Sang Hoon Chun, Seyoung Seo, Jang Ho Cho, Keon‐Uk Park, Sang‐Cheol Lee, Yong Won Choi, Tak Yun, Seong Hoon Shin, Sung‐Bae Kim, Seungeun Lee, Chang Ho Ahn, Bhumsuk Keam   +11 more
wiley   +1 more source

Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience

Advances in Radiation Oncology
Purpose: The current standard-of-care management of locally advanced triple negative breast cancer (TNBC) is based on neoadjuvant chemo-immunotherapy with pembrolizumab, surgery, radiation therapy (RT), and adjuvant pembrolizumab.
Thais Tison, MD, Pierre Loap, MD, Emilie Arnaud, MD, Kim Cao, MD, Solene Bringer, MD, Manon Kissel, MD, Safia Maaradji, MD, Juliette Mainguene, MD, Jean-Yves Pierga, MD, PhD, Florence Lerebours, MD, Anne Vincent-Salomon, MD, PhD, Mariana Mirabelle, MD, Francois-Clement Bidard, MD, PhD, Delphine Loirat, MD, PhD, Youlia M. Kirova, MD   +14 more
doaj   +1 more source

Visualization of Scattered Tumor Regression Following Neoadjuvant Chemoimmunotherapy With a Novel Intraoperative PET/CT Scanner

Head &Neck, EarlyView.
ABSTRACT Background Neoadjuvant chemoimmunotherapy is being explored in locally advanced head and neck squamous cell carcinoma (HNSCC), yet the spatial patterns of pathologic response and clinical implications remain poorly characterized. Methods A 79‐year‐old female with recurrent left oral tongue SCC (PD‐L122C3 Combined Positive Score 90) who ...
Andreja Radevic, Joaquin Austerlitz, Ashtyn McAdoo, Kyrionna Golliday, Takeshi Takahashi, Mitra Mehrad, Adam J. Rosenberg, Barbara A. Murphy, Eben Rosenthal, Michael C. Topf   +9 more
wiley   +1 more source

Pembrolizumab in HER2-Positive Gastric Cancer

Pembrolizumab in HER2-Positive Gastric Cancer The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy ...
Lowery, Maeve, Kawazoe, Akihito, Mahave, Mauricio, Tang, Yong, Shih, Chie-Schin, Ostapenko, Yuriy, Tabernero, Josep, Lonardi, Sara, Xu, Linzhi, Luo, Suxia, Janjigian, Yelena Y., Bhagia, Pooja, Yanez, Patricio, Van Cutsem, Eric, Sharan, Kanu P., Xu, Jianming, Bai, Yuxian, Shitara, Kohei, Bilici, Mehmet, Rha, Sun Young, Monteiro, Maria M. F., Shen, Lin, Chung, Hyun Cheol, Metges, Jean Phillipe, Qin, Shukui, Wyrwicz, Lucjan S.   +25 more
core   +1 more source

Clinicogenomic Features and Outcomes of Adenoid Cystic Carcinoma With Central Nervous System Metastases: A Single‐Institution Cohort Study

Head &Neck, EarlyView.
ABSTRACT Background Adenoid cystic carcinoma (ACC) is a rare malignancy with a propensity for perineural invasion and hematogenous spread. Central nervous system (CNS) involvement is uncommon, and detailed clinical and genomic data on this aspect of the disease remain limited.
Omar Elghawy, Jack Stylli, Martin Kurian, Eitan Halper‐Stromberg, Aditi Singh, Christopher D'Avella, Lee Hartner, Roger B. Cohen   +7 more
wiley   +1 more source

Real world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer

Background: Keynote 177 was a practice changing study, with pembrolizumab versus dealers’ choice chemotherapy +/- biologic significantly improving progression free survival in patients (pts) with previously untreated deficient mismatch repair (dMMR ...
Caird, Susan, Hong, Wei, Nott, Louise M, Tie, Jeanne, Wong, Rachel, Kosmider, Suzanne, Lim, Stephanie Hui-Su, Jennens, Ross, Steel, Simone Anne, Wong, Vanessa, Shapiro, Jeremy David, Lee, Belinda, Loft, Matthew, Khattak, Adnan, et al., Chong, Geoff   +15 more
core   +1 more source

A Case of Pembrolizumab Induced Papillitis With Transverse Myelitis

, 2021
Pembrolizumab is a humanized monoclonal antibody that inhibits programmed cell death-1 (PD-1) pathway resulting in an enhanced immune response. Currently, pembrolizumab is an approved treatment for cutaneous melanoma. Very few patients (
Ragha Chaitanya Sakuru; Merati Melody; Nathan Lambert-Cheatham; Sophia Tessema; Luke Salbert; Lina Nagia
core  

Early Feasibility of Registration of Micro‐PET/CT Scans to Annotated 3D Specimen Models

Head &Neck, EarlyView.
ABSTRACT Background Intraoperative 18F‐fluorodeoxyglucose (18F‐FDG) micro‐positron emission tomography/computed tomography (micro‐PET/CT) is an emerging modality for margin assessment. Prior to clinical use, micro‐PET/CT margin distances must be correlated with gold‐standard histopathology.
Joaquin Austerlitz, Andreja Radevic, Ashtyn McAdoo, Kyrionna Golliday, Cheng Ye, Daniel Fabbri, Adam J. Rosenberg, Marcus Balanky, Anas Alabkaa, Kim A. Ely, Mitra Mehrad, Spencer Roark, Eben Rosenthal, Michael C. Topf   +13 more
wiley   +1 more source